期刊文献+

帕布昔利布和氟维司群共载药阳离子脂质体的制备和性质评价 被引量:2

Preparation and Characterization of Cationic Liposomes Co-loaded with Palbociclib and Fulvestrant
下载PDF
导出
摘要 制备帕布昔利布(Pal)和氟维司群(Ful)共载药阳离子脂质体(cationic liposomes,CLs),对其物理化学性质进行表征.以二油酰磷脂酰乙醇胺和(2,3-二油酰基-丙基)-三甲胺为膜材,采用薄膜分散法制备帕布昔利布和氟维司群共载药阳离子脂质体(CLs),HPLC法测定共载药阳离子脂质体的包封率和载药量,激光粒度仪考察脂质体粒径和电位的分布情况,透射电子显微镜观察脂质体的形态.结果表明:Pal-Ful-CLs的平均粒径为(182.13±3.56)nm,多分散系数为0.18±0.02,表明分散度良好;Pal-Ful-CLs的电位为(57.1±2.6)mV,阳离子脂质体表面的正电荷有利于脂质体在体系中的均匀分散和稳定;在透射电子显微镜下观察到脂质体呈圆形且粒径与粒度仪测定结果一致.本研究制备的共载药阳离子脂质体粒径均一、分散稳定并且工艺重现性好,作为药物共同递送载体具有一定的应用前景. A novel type of cationic liposomes(CLs)co-loaded with pabuccilib(Pal)and fulvestrant(Ful)were prepared and their physicochemical properties were characterized in this study.With the dioleoyl phosphatidylethanolamine and(2,3-dioleoyl-propyl)-trimethylamine as membrane materials,a thin film dispersion method was used to prepare the cationic lipo-somes(CLs)co-drug-loaded cationic lipids of Pal and Ful HPLC method was used to determine the entrapment efficiency and drug loading of co-drug-loaded cationic liposomes;laser particle size analyzer was used to investigate the particle sizeand potential distribution of liposomes;the morphology of liposomes was observed by transmission electron microscope.Theresult of the study showed that the average particle size of Pal-Ful-CLs was(182.13±3.56)nm,and the polydispersity coeffi-cient was 0.18±0.02,indicating good dispersion;the potential of Pal-Ful-CLs was(57.1±2.6)mV,cationic liposomes The positive charge on the surface is beneficial to the uniform and stable dispersion of liposomes in the system;under the TEM,it was observed that the liposomes were round and the particle size was consistent with the results of the particle size analyzer.The co-drug-loaded cationic liposomes prepared in this study have uniform particle size,stable dispersion and good process reproducibility.They have certain application prospects as a drug delivery vehicle.
作者 李双双 吕佳琦 李媛 赵玙璠 滕玉鸥 李明媛 LI Shuangshuang;LÜJiaqi;LI Yuan;ZHAO Yufan;TENG Yuou;LI Mingyuan(College of Biotechnology,Tianjin University of Science&Technology,Tianjin 300457,China;Tianjin Enterprise Key Laboratory on Hyaluronic Acid Application Research,Tianjin Kangting Bioengineering Group Co.,Ltd.,Tianjin 300380,China)
出处 《天津科技大学学报》 CAS 2021年第4期8-13,31,共7页 Journal of Tianjin University of Science & Technology
基金 天津市教委“十三五综投”一般科研项目(2018KJ124) 天津市透明质酸应用研究企业重点实验室开放基金(天津市康婷生物工程集团有限公司,KTRDHA-Y201906)。
关键词 帕布昔利布 氟维司群 阳离子脂质体 共同递送 palbociclib fulvestrant cationic liposomes co-delivery
  • 相关文献

参考文献14

二级参考文献84

  • 1杨莉斌,胡荣.抗肿瘤药物脂质体粒径对肿瘤靶向性的影响[J].国外医学(药学分册),2007,34(3):174-176. 被引量:7
  • 2McGuire WP,Hoskins WJ,Brady MF,et al.Comparison of combination therapy with paclitaxel and cisplatin versus cyclophhosphamide and cisplatin in patients with suboptimal stage Ⅲ and stage Ⅳ ovarian cancer[J].Semin Oncol,1997,24(Suppl 2):13-16.
  • 3Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors:European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada [J].J Natl Cancer Inst,2000,92(3):205-216.
  • 4Rustin GJ,Nelstrop AE,Bentzen SM,et al.Use of tumour markers in monitoring the course of ovarian cancer [J].Ann Oncol,1999,10(supl 1):S21-S27.
  • 5McGuire WP,Hoskins WJ,Brady MF,et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer [J].N Engl J Med,1996,334:1-6.
  • 6Cheung VG,Conlin LK,Weber TM,et al.Natural variation in human gene expression assessed in lymphoblastoid cells [J].Nat Genet,2003,33:422-425.
  • 7Norton L.Evolving concepts in the systemic in drug therapy of breast cancer [J].Semin Oncol,1997,24:3-10.
  • 8Norton L,Simon R.The Norton-Simon hypothesis revisited.Cancer Treat Rep,1986,70:163-169.
  • 9Perez EA,Suman VJ,Davidson NE,et al.Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer.J Clin Oncol,2011,29(34):4491-4497.
  • 10Curran WJ Jr,Paulus R,Langer CJ,et al.Sequential vs.concurrent chemoradiation for stage III non-small cell lung cancer:randomized phase Ⅲ trial RTOG 9410 [J].J Natl Cancer Inst,2011,103(19):1452-1460.

共引文献101

同被引文献21

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部